These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 1363673

  • 1. Neuronal changes in the nigrostriatal pathway of 1-methyl-4-phenylpyridine-treated mice.
    Boatell ML, Mahy N, Cardozo A, Ambrosio S, Tolosa E, Cruz-Sánchez FF.
    Methods Find Exp Clin Pharmacol; 1992 Dec; 14(10):781-7. PubMed ID: 1363673
    [Abstract] [Full Text] [Related]

  • 2. Plasticity of the nigrostriatal system in MPTP-treated mice. A biochemical and morphological correlation.
    Cruz-Sanchez FF, Cardozo A, Ambrosio S, Tolosa E, Mahy N.
    Mol Chem Neuropathol; 1993 Dec; 19(1-2):163-76. PubMed ID: 8103334
    [Abstract] [Full Text] [Related]

  • 3. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
    Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM.
    J Neurosci Res; 2004 May 15; 76(4):539-50. PubMed ID: 15114626
    [Abstract] [Full Text] [Related]

  • 4. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
    Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T.
    Glia; 2003 May 15; 42(3):307-13. PubMed ID: 12673835
    [Abstract] [Full Text] [Related]

  • 5. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
    Aoki E, Yano R, Yokoyama H, Kato H, Araki T.
    Exp Mol Pathol; 2009 Feb 15; 86(1):57-64. PubMed ID: 19027004
    [Abstract] [Full Text] [Related]

  • 6. Fluoro-Jade C can specifically stain the degenerative neurons in the substantia nigra of the 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine-treated C57BL/6 mice.
    Bian GL, Wei LC, Shi M, Wang YQ, Cao R, Chen LW.
    Brain Res; 2007 May 30; 1150():55-61. PubMed ID: 17397812
    [Abstract] [Full Text] [Related]

  • 7. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice.
    Granado N, O'Shea E, Bove J, Vila M, Colado MI, Moratalla R.
    J Neurochem; 2008 Nov 30; 107(4):1102-12. PubMed ID: 18823368
    [Abstract] [Full Text] [Related]

  • 8. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
    Knyihár-Csillik E, Csillik B, Pákáski M, Krisztin-Péva B, Dobó E, Okuno E, Vécsei L.
    Neuroscience; 2004 Nov 30; 126(4):899-914. PubMed ID: 15207325
    [Abstract] [Full Text] [Related]

  • 9. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R, Muramatsu Y, Kato H, Watanabe Y, Imai Y, Itoyama Y, Araki T.
    Eur Neuropsychopharmacol; 2005 Jan 30; 15(1):57-67. PubMed ID: 15572274
    [Abstract] [Full Text] [Related]

  • 10. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L, Garris BL, Garris DR, Lau YS.
    Neuroscience; 2006 Jun 19; 140(1):67-76. PubMed ID: 16533572
    [Abstract] [Full Text] [Related]

  • 11. Pyrethroid and organophosphate insecticide exposure in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease: an immunohistochemical analysis of tyrosine hydroxylase and glial fibrillary acidic protein in dorsolateral striatum.
    Dodd CA, Klein BG.
    Toxicol Ind Health; 2009 Feb 19; 25(1):25-39. PubMed ID: 19318502
    [Abstract] [Full Text] [Related]

  • 12. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
    Tripanichkul W, Sripanichkulchai K, Finkelstein DI.
    Brain Res; 2006 Apr 21; 1084(1):28-37. PubMed ID: 16564034
    [Abstract] [Full Text] [Related]

  • 13. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice.
    Mitsumoto Y, Watanabe A, Mori A, Koga N.
    Biochem Biophys Res Commun; 1998 Jul 30; 248(3):660-3. PubMed ID: 9703982
    [Abstract] [Full Text] [Related]

  • 14. The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity.
    O'Callaghan JP, Martin PM, Mass MJ.
    Ann N Y Acad Sci; 1998 May 30; 844():40-9. PubMed ID: 9668663
    [Abstract] [Full Text] [Related]

  • 15. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK, Keyghobadi M, Moore C, Meshul CK.
    Neuroscience; 2005 May 30; 136(1):333-41. PubMed ID: 16198485
    [Abstract] [Full Text] [Related]

  • 16. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
    Holmer HK, Keyghobadi M, Moore C, Menashe RA, Meshul CK.
    Synapse; 2005 Aug 30; 57(2):100-12. PubMed ID: 15906381
    [Abstract] [Full Text] [Related]

  • 17. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J, Wang YY, Liu L, Wang QD, Yuan ZY, Zhang ZX, Gu P, Wang MW.
    Neurosci Lett; 2008 Dec 26; 448(2):184-8. PubMed ID: 18977411
    [Abstract] [Full Text] [Related]

  • 18. Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.
    Luellen BA, Miller DB, Chisnell AC, Murphy DL, O'Callaghan JP, Andrews AM.
    J Pharmacol Exp Ther; 2003 Dec 26; 307(3):923-31. PubMed ID: 14561848
    [Abstract] [Full Text] [Related]

  • 19. Manganese does not alter the severe neurotoxicity of MPTP.
    Baek SY, Kim YH, Oh SO, Lee CR, Yoo CI, Lee JH, Lee H, Sim CS, Park J, Kim JW, Yoon CS, Kim Y.
    Hum Exp Toxicol; 2007 Mar 26; 26(3):203-11. PubMed ID: 17439923
    [Abstract] [Full Text] [Related]

  • 20. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW, Bradbury KA, Schneider JS.
    Eur J Neurosci; 2006 Dec 26; 24(11):3174-82. PubMed ID: 17156378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.